Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial of a potential treatment for Ebola has started in Liberia, with the first Ebola patient receiving the study drug on 2 January.

The trial is led by the University of Oxford and is taking place at Médecins Sans Frontières (MSF)’s ELWA 3 Ebola Management Centre in Monrovia.

Funded by the Wellcome Trust, the trial aims to evaluate the effectiveness of an oral antiviral drug called brincidofovir in patients with Ebola virus disease. Brincidofovir is an experimental drug made by the US company Chimerix in Durham, North Carolina.

Read more